Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$57.99
+1.3%
$58.69
$49.26
▼
$70.98
$10.98B0.212.53 million shs2.02 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$125.85
-1.3%
$117.14
$62.91
▼
$142.92
$10.86B2.04975,533 shs912,369 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$11.82
-16.5%
$16.30
$11.52
▼
$29.23
$12.06B-1.494.78 million shs24.44 million shs
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$29.80
-3.5%
$22.88
$13.18
▼
$34.29
$3.46B1.072.95 million shs2.09 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%+2.14%+4.66%-14.12%+4.57%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
0.00%-3.16%+21.75%+5.07%+96.44%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%-13.35%-3.28%+10.72%-21.52%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.00%+8.35%+62.22%+33.69%+7.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$57.99
+1.3%
$58.69
$49.26
▼
$70.98
$10.98B0.212.53 million shs2.02 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$125.85
-1.3%
$117.14
$62.91
▼
$142.92
$10.86B2.04975,533 shs912,369 shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$11.82
-16.5%
$16.30
$11.52
▼
$29.23
$12.06B-1.494.78 million shs24.44 million shs
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$29.80
-3.5%
$22.88
$13.18
▼
$34.29
$3.46B1.072.95 million shs2.09 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.00%+2.14%+4.66%-14.12%+4.57%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
0.00%-3.16%+21.75%+5.07%+96.44%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%-13.35%-3.28%+10.72%-21.52%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.00%+8.35%+62.22%+33.69%+7.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.80
Moderate Buy$87.2250.40% Upside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2.89
Moderate Buy$139.1610.58% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.58
Moderate Buy$28.38140.08% Upside
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
2.83
Moderate Buy$41.0037.58% Upside

Current Analyst Ratings Breakdown

Latest VRDN, SMMT, KYMR, and BMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Lower Price TargetBuy$43.00 ➝ $42.00
11/16/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Lower Price TargetEqual Weight$20.00 ➝ $18.00
11/15/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Reiterated RatingBuy
11/13/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Lower Price TargetOverweight$119.00 ➝ $103.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetOutperform$38.00 ➝ $41.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetOutperform$50.00 ➝ $54.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetBuy$39.00 ➝ $42.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetOverweight$31.00 ➝ $34.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetOutperform$41.00 ➝ $42.00
11/5/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetBuy$22.00 ➝ $40.00
11/4/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Lower Price TargetOverweight$87.00 ➝ $86.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B3.49$2.92 per share19.87$32.30 per share1.80
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$39.21M274.01N/AN/A$18.91 per share6.66
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.71 per shareN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$70.85M47.76N/AN/A$4.25 per share7.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M-$0.1031.8511.280.76-0.52%5.58%3.51%N/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$311.35M-$3.62N/AN/AN/A-285.33%-22.39%-20.48%N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.07N/AN/AN/AN/A-138.82%-117.11%N/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$342.60M-$3.84N/AN/AN/A-1,620.79%-79.67%-44.72%N/A

Latest VRDN, SMMT, KYMR, and BMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$1.02-$0.81+$0.21-$0.81$4.72 million$25.75 million
11/2/2026Q3 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-$0.0493$0.23+$0.2793-$0.63$1.02 billion$1.02 billion
10/29/2026Q3 2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$1.26-$1.32-$0.06-$1.32$3.28 million$1.35 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.44
1.32
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
11.13
11.13
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
5.99
5.99
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.50
14.46
14.46

Institutional Ownership

CompanyInstitutional Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.70 million192.38 millionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
28585.37 million71.73 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265799.76 million145.56 millionOptionable
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
252113.56 million110.83 millionOptionable

Recent News About These Companies

HC Wainwright Has Strong Forecast for VRDN FY2026 Earnings
Q4 Earnings Forecast for VRDN Issued By HC Wainwright
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $40.00
Analysts Offer Predictions for VRDN Q4 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$57.99 +0.76 (+1.33%)
Closing price 04:00 PM Eastern
Extended Trading
$58.00 +0.02 (+0.03%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$125.85 -1.72 (-1.35%)
Closing price 04:00 PM Eastern
Extended Trading
$121.36 -4.49 (-3.57%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$11.82 -2.33 (-16.47%)
Closing price 04:00 PM Eastern
Extended Trading
$11.85 +0.03 (+0.25%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Viridian Therapeutics stock logo

Viridian Therapeutics NASDAQ:VRDN

$29.80 -1.07 (-3.47%)
Closing price 04:00 PM Eastern
Extended Trading
$29.82 +0.02 (+0.07%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.